Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression

被引：0
|
作者：
Riedel, R. [1 ]
Michels, S. [1 ]
Heydt, C. [2 ]
Nogova, L. [1 ]
Fischer, R. N. [1 ]
Abdulla, D. S. Y. [1 ]
Scheffler, M. [1 ]
Merkelbach-Bruse, S. [2 ]
Kobe, C. [3 ]
Schaefer, S. [2 ]
Buettner, R. [2 ]
Wolf, J. [1 ]
机构：
[1] Uniklin Koln, Klin Innere Med 1, Cologne, Germany
[2] Uniklin Koln, Inst Pathol, Cologne, Germany
[3] Uniklin Koln, Klin Nukl Med, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P910
引用
收藏
页码：295 / 296
页数：2
相关论文
共 50 条
  • [1] Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
    Riedel, Richard
    Michels, Sebastian
    Heydt, Carina
    Siemanowski, Janna
    Kobe, Carsten
    Bunck, Anne
    Schaefer, Stephan
    Fischer, Rieke N.
    Scheffler, Matthias
    Abdulla, Diana S. Y.
    Nogova, Lucia
    Koleczko, Sophia
    Merkelbach-Bruse, Sabine
    Buettner, Reinhard
    Wolf, Juergen
    LUNG CANCER, 2019, 133 : 20 - 22
  • [2] Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification
    Cil, Ibrahim
    Zirtiloglu, Alisan
    Saydam, Nurbanu
    Tural, Deniz
    JOURNAL OF BUON, 2017, 22 (01): : 279 - 280
  • [3] Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
    Jenkins, Russell W.
    Oxnard, Geoffrey R.
    Elkin, Sheryl
    Sullivan, E. Kelly
    Carter, Jennifer L.
    Barbie, David A.
    CLINICAL LUNG CANCER, 2015, 16 (05) : E101 - E104
  • [4] MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma
    Suryavanshi, Moushumi
    Shah, Aekta
    Kumar, Dushyant
    Panigrahi, Manoj K.
    Metha, Anurag
    Batra, Ullas
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (04) : 198 - +
  • [5] MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
    Yin, Wei
    Guo, Ming
    Tang, Zhenya
    Toruner, Gokce A.
    Cheng, Joanne
    Medeiros, L. Jeffrey
    Tang, Guilin
    CANCERS, 2022, 14 (10)
  • [6] Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
    Leyrat, Brice
    Durando, Xavier
    Veyssiere, Hugo
    Bernadach, Maureen
    ONCOTARGETS AND THERAPY, 2021, 14 : 3949 - 3958
  • [7] Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report
    Liu, Junfang
    Shen, Lijun
    Qian, Yunyao
    Liu, Yunpeng
    Su, Minhong
    Yi, Li
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2931 - 2935
  • [8] Interest of crizotinib in a lung cancer patient with de novo amplification of MET
    Rabeau, A.
    Rouquette, I.
    Vantelon, J. -M.
    Taranchon-Clermont, E.
    Mazieres, J.
    REVUE DES MALADIES RESPIRATOIRES, 2017, 34 (01) : 57 - 60
  • [9] Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report
    Aubanel, Marjorie
    Swalduz, Aurelie
    Avrillon, Virginie
    Doublet, Louis
    Mastroianni, Benedicte
    Neidhardt-Berard, Eve-Marie
    Perol, Maurice
    CLINICAL LUNG CANCER, 2020, 21 (06) : E601 - E606
  • [10] Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation
    Rotow, Julia K.
    Woodard, Gavitt A.
    Urisman, Anatoly
    McCoach, Caroline E.
    Bivona, Trever G.
    Elicker, Brett M.
    Jablons, David M.
    Blakely, Collin M.
    CLINICAL LUNG CANCER, 2019, 20 (02) : E137 - E141
12345